Home > Companies > NAMM California

NAMM California

nammcal.com

North American Medical Management (NAMM) California, Inc., part of OptumCare®, develops and manages provider networks, offering a full range of services to assist physicians and other providers in their managed care and business operations (the “Clients”). For 25 years, NAMM has been an innovator in health care with a track record for quality, financial stability, extraordinary services and superior electronic capabilities. NAMM is well positioned to continually invest in its infrastructure and systems for the benefit of its Clients and to accommodate the impending changes that will come forth from healthcare reform. The NAMM Clients represent a network of over 600 primary care physicians and 1,500 specialists and work with the premier hospitals in their respective markets.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

5th International Conference on Biotechnology, Biomedicines and Genetic Engineering

Conference

International Conference on Biodiversity and Conservation (ICBC-24)

Conference

BIO Patient & Health Advocacy Summit

Conference

27th World Congress on Biotechnology

Conference

11th International Conference on Biotechnology Research

Conference

European Congress on Biopolymers and Bioplastics

Conference

Related News

LILLY AND SITRYX SIGN $880 MILLION+ 5-YEAR DEVELOPMENT DEAL

BioSpace | March 31, 2020

Eli Lilly and Oxford, England-based Sitryx entered an exclusive global licensing and research collaboration. The two companies will work to develop up to four preclinical compounds discovered by Sitryx for autoimmune diseases. Under the terms of the deal, Lilly is paying Sitryx $50 million up front. Lilly will also make a $10 million equity investment in the company. Sitryx will be eligible for development milestones up to $820 million, in addition to commercialization milestones and royalty pay...

MedTech, Industry Outlook

VAXXINITY DEMONSTRATES TARGET ENGAGEMENT OF TOXIC ALPHA-SYNUCLEIN IN PARKINSON’S PATIENTS

Globenewswire | July 18, 2023

Vaxxinity, Inc. a U.S. company pioneering the development of a new class of medicines, announced new data from a Phase 1 clinical trial demonstrating that antibodies derived from its investigational immunotherapeutic for Parkinson’s disease (PD), UB-312, slows seeding of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) of patients with PD as demonstrated using multiple target engagement assays. These data signify that UB-312 has established clear target engagement in PD patient CS...

Cell and Gene Therapy

CASMA THERAPEUTICS RAISES $46.0 M IN SERIES C FUNDING

Casma Therapeutics, Inc. | November 21, 2022

Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono Venture Investment. Current investors Eventide Asset Management, LLC, Schroders Capital, The Column Group, Third Rock Ventures, and other funds also particip...

BIOLOGICAL DYNAMICS EXPANDS BIOMARKERS RESEARCH TO DEVELOP ASSAYS FOR DETECTION AND QUANTIFICATION OF BLOOD-BASED BIOMARKERS

Biological Dynamics | July 30, 2020

Biological Dynamics, Inc., an innovative diagnostic company committed to improving global health, announces a new biomarkers program designed for drug development applications in Alzheimer's Disease (AD). The company will use its proprietary Verita™ platform to develop a portfolio of assays for detection and quantification of blood-based biomarkers associated with AD and other neurodegenerative conditions. The program is funded by the Alzheimer's Drug Discovery Foundation's (AD...